The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
Browsing: AbbVie
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…
iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…
Pediatric Patients with CGvHD Ibrutinib OK’d by FDA Â Chronic graft versus host disease, or CGvHD, is a condition associated…